Alogliptin improves endothelial function by promoting autophagy in perivascular adipose tissue of obese mice through a GLP-1-dependent mechanism

Vascul Pharmacol. 2019 Apr:115:55-63. doi: 10.1016/j.vph.2018.11.003. Epub 2018 Nov 14.

Abstract

Objective: Perivascular adipose tissue (PVAT) regulates vascular function in a paracrine manner and the vasodilatory effect of PVAT on vessels is completely abolished in obesity. In addition, autophagy is required for maintaining biological function of PVAT and has been shown to be inhibited in obesity. The aim of this study was to explore whether alogliptin improves endothelial function by promoting autophagy in PVAT in obese mice.

Methods: C57BL/6 mice were maintained on high fat diet with or without alogliptin intervention for 3 months. Vasorelaxation function of thoracic aorta with or without PVAT was determined. Autophagy related protein level of p62 and LC3B, along with phosphorylated mTOR (p-mTOR) were evaluated. In addition, the effects of alogliptin on autophagy were also investigated in cultured adipocytes.

Results: The presence of PVAT significantly impaired endothelium-dependent vasodilation in obese mice and alogliptin intervention corrected this defect. Autophagy in PVAT was decreased in obese mice and alogliptin intervention activated autophagy. Activating autophagy in PVAT improved endothelium-dependent vasodilation while blocking it in PVAT impaired vasodilation function. Further, addition of glucagon-like peptide-1 (GLP-1) but not alogliptin alone activated autophagy. Moreover, GLP-1 and alogliptin co-treatment did not show additive effect on activating autophagy.

Conclusions: These results revealed that promoting autophagy in PVAT improved endothelial function in response to alogliptin intervention. Additionally, the beneficial effect of alogliptin intervention on PVAT was GLP-1 dependent.

Keywords: Alogliptin; Autophagy; Dipeptidyl peptidase-4 inhibitor; Endothelial function; GLP-1; Perivascular adipose tissue.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipokines / metabolism
  • Adipose Tissue / drug effects*
  • Adipose Tissue / metabolism
  • Adipose Tissue / pathology
  • Adipose Tissue / physiopathology
  • Animals
  • Aorta, Thoracic / drug effects*
  • Aorta, Thoracic / metabolism
  • Aorta, Thoracic / physiopathology
  • Autophagy / drug effects*
  • Dipeptidyl-Peptidase IV Inhibitors / pharmacology*
  • Disease Models, Animal
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / physiopathology
  • Glucagon-Like Peptide 1 / metabolism*
  • Male
  • Mice, Inbred C57BL
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type III / metabolism
  • Obesity / drug therapy*
  • Obesity / metabolism
  • Obesity / pathology
  • Obesity / physiopathology
  • Paracrine Communication / drug effects
  • Piperidines / pharmacology*
  • Proto-Oncogene Proteins c-akt / metabolism
  • Signal Transduction / drug effects
  • Uracil / analogs & derivatives*
  • Uracil / pharmacology
  • Vasodilation / drug effects*

Substances

  • Adipokines
  • Dipeptidyl-Peptidase IV Inhibitors
  • Piperidines
  • Nitric Oxide
  • Uracil
  • Glucagon-Like Peptide 1
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse
  • Proto-Oncogene Proteins c-akt
  • alogliptin